Målrettet behandling af lymfoproliferativ sygdom: kinasehæmmere og Bcl-2-hæmmere

Carsten Utoft Niemann; Christian Hartmann Geisler

Målrettet behandling af lymfoproliferativ sygdom: kinasehæmmere og Bcl-2-hæmmere

Carsten Utoft Niemann, Christian Hartmann Geisler

IKM

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Abstract

The development of targeted treatment of chronic lymphocytic leukaemia (CLL) is changing the prognostic outlook for CLL patients. The B-cell antigen receptor pathway is identified as pivotal for CLL pathogenesis and CLL cell proliferation. Inhibition of this pathway by ibrutinib (Bruton's tyrosin kinase inhibition) and idelalisib (phosphatidylinositol 3-kinase inhibition) has recently shown impressive clinical results, also for CLL patients with relapsed/refractory disease and unfavourable prognostic markers. Apoptosis induction by inhibition of BCL2 with ABT-199 is reported with likewise promising clinical results.

Bidragets oversatte titel	Targeted treatment of chronic lymphocytic leukaemia.
Originalsprog	Dansk
Artikelnummer	V66229
Tidsskrift	Ugeskrift for Laeger
Vol/bind	176
Udgave nummer	11A
Sider (fra-til)	1
Antal sider	1
ISSN	0041-5782
Status	Udgivet - 7 apr. 2014

Citationsformater

@article{58005b4f23434501a5313509157292e8,

title = "M{\aa}lrettet behandling af lymfoproliferativ sygdom: kinaseh{\ae}mmere og Bcl-2-h{\ae}mmere ",

abstract = "The development of targeted treatment of chronic lymphocytic leukaemia (CLL) is changing the prognostic outlook for CLL patients. The B-cell antigen receptor pathway is identified as pivotal for CLL pathogenesis and CLL cell proliferation. Inhibition of this pathway by ibrutinib (Bruton's tyrosin kinase inhibition) and idelalisib (phosphatidylinositol 3-kinase inhibition) has recently shown impressive clinical results, also for CLL patients with relapsed/refractory disease and unfavourable prognostic markers. Apoptosis induction by inhibition of BCL2 with ABT-199 is reported with likewise promising clinical results.",

author = "Niemann, {Carsten Utoft} and Geisler, {Christian Hartmann}",

year = "2014",

month = apr,

day = "7",

language = "Dansk",

volume = "176",

pages = "1",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "11A",

}

TY - JOUR

T1 - Målrettet behandling af lymfoproliferativ sygdom

T2 - kinasehæmmere og Bcl-2-hæmmere

AU - Niemann, Carsten Utoft

AU - Geisler, Christian Hartmann

PY - 2014/4/7

Y1 - 2014/4/7

N2 - The development of targeted treatment of chronic lymphocytic leukaemia (CLL) is changing the prognostic outlook for CLL patients. The B-cell antigen receptor pathway is identified as pivotal for CLL pathogenesis and CLL cell proliferation. Inhibition of this pathway by ibrutinib (Bruton's tyrosin kinase inhibition) and idelalisib (phosphatidylinositol 3-kinase inhibition) has recently shown impressive clinical results, also for CLL patients with relapsed/refractory disease and unfavourable prognostic markers. Apoptosis induction by inhibition of BCL2 with ABT-199 is reported with likewise promising clinical results.

AB - The development of targeted treatment of chronic lymphocytic leukaemia (CLL) is changing the prognostic outlook for CLL patients. The B-cell antigen receptor pathway is identified as pivotal for CLL pathogenesis and CLL cell proliferation. Inhibition of this pathway by ibrutinib (Bruton's tyrosin kinase inhibition) and idelalisib (phosphatidylinositol 3-kinase inhibition) has recently shown impressive clinical results, also for CLL patients with relapsed/refractory disease and unfavourable prognostic markers. Apoptosis induction by inhibition of BCL2 with ABT-199 is reported with likewise promising clinical results.

M3 - Tidsskriftartikel

C2 - 25350143

SN - 0041-5782

VL - 176

SP - 1

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 11A

M1 - V66229

ER -